龙沙集团仍计划出售其胶囊与健康配料业务
Lonza still intends to sell its capsules and health ingredients business
生物技术与制药领域的最新动态
Lonza still intends to sell its capsules and health ingredients business
Lonza still intends to sell its capsules and health ingredients business - Endpoints News
Earnings call transcript: Lonza reports strong 2025 results, stock dips - Investing.com
Lonza Sees Steady 2026 Growth After A Strong 2025 - Finimize
Switzerland's Lonza edges closer to sale of its capsule and health ingredients business - Reuters
Lonza delivers strong profitable growth in 2025 - The Pharma Letter
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - wkzo.com
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - MSN
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - Global Banking & Finance Review
Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration - TradingView
Lonza Group AG (LONN.SW, SIX): CHF550.20 intraday ahead of 28 Jan earnings — what to watch - Meyka
CHF555.20 Lonza Group AG (LONN.SW, SIX) intraday before Jan 28 earnings: key metrics to watch - Meyka
Cell Therapy Bioprocessing Market Is Going to Boom |• Lonza • Thermo Fisher Scientific - openPR.com
Lonza Group (OTCMKTS:LZAGY) Sees Large Volume Increase - Time to Buy? - MarketBeat
Industry Roundtable: Small-Molecule APIs: What’s in Store for 2026? - DCAT Value Chain Insights
Lonza Group (OTCMKTS:LZAGY) Trading Down 1.8% - What's Next? - MarketBeat